Why XBB and BQ.1 become dominant in highly diversified Omicron subvariants?

In late 2022, although the dominant variants of SARS-CoV-2 have highly diversified, these Omicron subvariants have a characteristic of convergent evolution.

Among these variants, BQ.1, which spread rapidly in Europe, and XBB, which spread rapidly in Asia, were thought as two of the most dangerous lineages. The results of current research showed that BQ.1, BQ.1.1, XBB and XBB.1 have the strongest immune escape to neutralizing antibodies induced by almost all variants, including BA.5. The effectiveness of the latest bivalent mRNA vaccine and all therapeutic antibodies so far were decreased or disappeared to these lineages, which means that people who have vaccinated or Infected may be reinfected.

At ACROBiosystems, we remain committed to contributing to the efforts against COVID-19. To support the variants research and new vaccine and therapeutic antibodies R&D, we developed antigens of a series of variants including XBB and BQ.1.1

BQ.1	BQ.1.1	XBB	XBB.1	BJ.1
BQ.1.1.10	BQ.1.1.11	BN.1	CH.1.1	……more

>>>Click on the column to learn more

>>>Click on the banner to learn more about related products

ACRO'S Insight

Tackling Solid Tumors:The Next Hurdle for Cell Therapies

Chimeric antigen receptor T cell (CAR-T) therapies such as Kymriah and Yescarta, have been hailed as a significant breakthrough in treatment of hematological malignancies. However, the limitations of approved CAR-T therapies were evident when it came to treating solid tumors. Overcoming this hurdle has become one of the primary research goals for cell therapies, especially since solid tumors account for over 90% of all diagnosed cancers......

Read Online

To receive the latest industry news and updates from ACROBiosystems,

visit our website & follow us on our social media!

Visit our Website